Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

Agreement/Product LaunchStraumann Group to present its advanced digital dentistry end-to-end workflow at the International Dental Show in Cologne 25.03.2025 / 07:00 CET/CEST Straumann AXS cloud-based ...

By Tatyana Kekic in Belgrade Serbia's political landscape remains in flux after the resignation of Prime Minister Milos ...

Advisors Asset Management Inc. trimmed its stake in Regeneron Pharmaceuticals by 7.9%, selling 443 shares in the fourth ...

Merck & Co. is flexing its pharmaceutical muscles with strong dividend growth, steady cash flow, and a blockbuster cancer ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

We Store Frozen is proud to announce the grand opening of its 180,000-square-foot cold storage facility in Houston, Texas. This expansion represents a significant milestone for the company and ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...